XBIO — Xenetic Biosciences Balance Sheet
0.000.00%
- $4.27m
- -$1.89m
- $2.50m
- 27
- 51
- 10
- 19
Annual balance sheet for Xenetic Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 11.5 | 18.2 | 13.1 | 8.98 | 6.17 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 12.4 | 18.7 | 13.7 | 9.59 | 6.59 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.027 | 0 | — | — | — |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 13.2 | 19.8 | 14.7 | 10.6 | 6.9 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 0.937 | 1.42 | 1.07 | 0.81 | 0.894 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.964 | 1.42 | 1.07 | 0.81 | 0.894 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 12.2 | 18.4 | 13.6 | 9.8 | 6.01 |
Total Liabilities & Shareholders' Equity | 13.2 | 19.8 | 14.7 | 10.6 | 6.9 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |